Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.

• Anti-angiotensin II receptor subtype 1 (AT1 receptor) autoantibodies have previously been shown in sera of hypertensive patients. This study assessed whether anti-AT1-receptor autoantibody in serum is correlated with the efficacy of an AT1-receptor blocker (ARB; candesartan)-based regimen in hypertensive patients after 8 weeks of treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

Adult

Aged

Angiotensin II Type 1 Receptor Blockers

therapeutic use

Antihypertensive Agents

adverse effects

therapeutic use

Autoantibodies

blood

Benzimidazoles

adverse effects

therapeutic use

Blood Pressure

drug effects

Double-Blind Method

Female

Humans

Hypertension

drug therapy

immunology

physiopathology

Imidazolidines

adverse effects

therapeutic use

Male

Middle Aged

Receptor

Angiotensin

Type 1

immunology

Tetrazoles

adverse effects

therapeutic use

Treatment Outcome

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)